Compare GHG & SGHT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
GreenTree Hospitality Group Ltd. American depositary shares each representing one ordinary share
Current Price
Current Price
| Metric | GHG | SGHT |
|---|---|---|
| Founded | 2004 | 2011 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Hotels/Resorts | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 171.6M | 187.4M |
| IPO Year | 2017 | 2021 |
| Metric | GHG | SGHT |
|---|---|---|
| Price | $1.20 | $3.80 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $9.08 |
| AVG Volume (30 Days) | 21.3K | ★ 389.5K |
| Earning Date | 04-23-2026 | 03-04-2026 |
| Dividend Yield | ★ 4.25% | N/A |
| EPS Growth | N/A | ★ 28.16 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $77,363,000.00 |
| Revenue This Year | $19.02 | $11.81 |
| Revenue Next Year | $8.26 | $10.62 |
| P/E Ratio | $5.76 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.14 | $2.03 |
| 52 Week High | $2.78 | $9.24 |
| Indicator | GHG | SGHT |
|---|---|---|
| Relative Strength Index (RSI) | 38.64 | 40.10 |
| Support Level | $1.17 | $3.29 |
| Resistance Level | $1.35 | $4.34 |
| Average True Range (ATR) | 0.07 | 0.21 |
| MACD | 0.00 | 0.09 |
| Stochastic Oscillator | 36.36 | 54.29 |
GreenTree Hospitality Group Ltd is a franchised hotel operator in China as franchised and managed hotels represent almost all the hotels in its hotel network. The hotel network of the company comprised approximately 4,059 hotels with nearly 302,497 rooms in China, covering all centrally administrated municipalities and cities throughout all provinces and autonomous regions in China. The company operates its hotels under GreenTree Inns, GreenTree Eastern, Gme, Gya and VX, GreenTree Alliance, Vatica, and others. The company operates solely in China and generates all its revenue from China itself.
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. The company operates through two segments: Interventional Glaucoma, which generates the majority of revenue and includes the OMNI Surgical System family of products and the SION Surgical Instrument used in minimally invasive glaucoma surgery to reduce intraocular pressure in adult patients with open-angle glaucoma; and Interventional Dry Eye, which includes the TearCare System, an interventional device designed to melt and facilitate the removal of meibomian gland obstructions and restore gland functionality in adult patients with evaporative dry eye disease.